vs
Side-by-side financial comparison of Citius Pharmaceuticals, Inc. (CTXR) and U S GLOBAL INVESTORS INC (GROW). Click either name above to swap in a different company.
Citius Pharmaceuticals, Inc. is the larger business by last-quarter revenue ($3.9M vs $2.5M, roughly 1.6× U S GLOBAL INVESTORS INC). U S GLOBAL INVESTORS INC runs the higher net margin — -33.7% vs -238.2%, a 204.5% gap on every dollar of revenue.
Citius Pharmaceuticals, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing innovative prescription therapies addressing unmet medical needs across critical care, oncology, anti-infective treatment, and supportive care segments, primarily serving the U.S. healthcare market.
Allianz Global Investors, is a global investment management firm with offices in over 20 locations worldwide. It is owned by the global financial services group Allianz. Employing nearly 3,000, it manages over EUR 500 billion in assets on behalf of institutional, retail clients and also of Allianz itself. AGI became known for one of the biggest fraud cases in which its Structured Alpha fund lost over 6 billion dollars in the 2020 market sell-off. As the risk profile of the fund was missold to...
CTXR vs GROW — Head-to-Head
Income Statement — Q1 FY2026 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $3.9M | $2.5M |
| Net Profit | $-9.4M | $-846.0K |
| Gross Margin | 80.0% | — |
| Operating Margin | -228.7% | -3.5% |
| Net Margin | -238.2% | -33.7% |
| Revenue YoY | — | 12.5% |
| Net Profit YoY | 8.6% | -883.7% |
| EPS (diluted) | $-0.38 | $-0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $3.9M | $2.5M | ||
| Q3 25 | — | $2.3M | ||
| Q2 25 | — | $2.0M | ||
| Q1 25 | — | $2.1M | ||
| Q4 24 | — | $2.2M | ||
| Q3 24 | — | $2.2M | ||
| Q2 24 | — | $2.4M | ||
| Q1 24 | — | $2.6M |
| Q4 25 | $-9.4M | $-846.0K | ||
| Q3 25 | — | $1.5M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | $-382.0K | ||
| Q4 24 | — | $-86.0K | ||
| Q3 24 | — | $315.0K | ||
| Q2 24 | — | $315.0K | ||
| Q1 24 | — | $-35.0K |
| Q4 25 | 80.0% | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | -228.7% | -3.5% | ||
| Q3 25 | — | -22.9% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -42.5% | ||
| Q4 24 | — | -24.2% | ||
| Q3 24 | — | -25.9% | ||
| Q2 24 | — | — | ||
| Q1 24 | — | -18.8% |
| Q4 25 | -238.2% | -33.7% | ||
| Q3 25 | — | 66.9% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -18.2% | ||
| Q4 24 | — | -3.9% | ||
| Q3 24 | — | 14.6% | ||
| Q2 24 | — | 12.9% | ||
| Q1 24 | — | -1.3% |
| Q4 25 | $-0.38 | $-0.07 | ||
| Q3 25 | — | $0.12 | ||
| Q2 25 | — | — | ||
| Q1 25 | — | $-0.03 | ||
| Q4 24 | — | $-0.01 | ||
| Q3 24 | — | $0.02 | ||
| Q2 24 | — | $0.01 | ||
| Q1 24 | — | $0.00 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $7.7M | $34.4M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $80.0M | $44.2M |
| Total Assets | $140.4M | $47.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $7.7M | $34.4M | ||
| Q3 25 | — | $34.3M | ||
| Q2 25 | — | $34.2M | ||
| Q1 25 | — | $36.0M | ||
| Q4 24 | — | $35.7M | ||
| Q3 24 | — | $37.0M | ||
| Q2 24 | — | $37.0M | ||
| Q1 24 | — | $37.5M |
| Q4 25 | $80.0M | $44.2M | ||
| Q3 25 | — | $46.0M | ||
| Q2 25 | — | $45.2M | ||
| Q1 25 | — | $46.1M | ||
| Q4 24 | — | $47.3M | ||
| Q3 24 | — | $48.4M | ||
| Q2 24 | — | $49.0M | ||
| Q1 24 | — | $49.7M |
| Q4 25 | $140.4M | $47.2M | ||
| Q3 25 | — | $48.9M | ||
| Q2 25 | — | $48.1M | ||
| Q1 25 | — | $48.8M | ||
| Q4 24 | — | $50.1M | ||
| Q3 24 | — | $51.1M | ||
| Q2 24 | — | $52.0M | ||
| Q1 24 | — | $52.8M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-13.0M | $256.0K |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-13.0M | $256.0K | ||
| Q3 25 | — | $-32.0K | ||
| Q2 25 | — | $-822.0K | ||
| Q1 25 | — | $-425.0K | ||
| Q4 24 | — | $-399.0K | ||
| Q3 24 | — | $16.0K | ||
| Q2 24 | — | $990.0K | ||
| Q1 24 | — | $-57.0K |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $-829.0K | ||
| Q1 25 | — | $-426.0K | ||
| Q4 24 | — | $-406.0K | ||
| Q3 24 | — | — | ||
| Q2 24 | — | $777.0K | ||
| Q1 24 | — | $-125.0K |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | -42.3% | ||
| Q1 25 | — | -20.3% | ||
| Q4 24 | — | -18.2% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 31.8% | ||
| Q1 24 | — | -4.8% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 0.4% | ||
| Q1 25 | — | 0.0% | ||
| Q4 24 | — | 0.3% | ||
| Q3 24 | — | 0.0% | ||
| Q2 24 | — | 8.7% | ||
| Q1 24 | — | 2.6% |
| Q4 25 | — | — | ||
| Q3 25 | — | -0.02× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 0.05× | ||
| Q2 24 | — | 3.14× | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
